carmustine has been researched along with Sensitivity and Specificity in 7 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 7.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 3.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| "Diffusion MRI could detect water diffusion changes in orthotopic 9L gliomas after doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) that resulted in as little as 0." | 3.70 | Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. ( Chenevert, TL; Greenberg, HS; Rehemtulla, A; Robertson, PL; Ross, BD; Stegman, LD; Taylor, JM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Satomi, K | 1 |
| Matsuda, M | 1 |
| Akutsu, H | 1 |
| Shibuya, M | 1 |
| Nakai, K | 1 |
| Sakamoto, N | 1 |
| Takano, S | 1 |
| Matsumura, A | 1 |
| Hoff, BA | 1 |
| Chenevert, TL | 2 |
| Bhojani, MS | 1 |
| Kwee, TC | 1 |
| Rehemtulla, A | 2 |
| Le Bihan, D | 1 |
| Ross, BD | 2 |
| Galbán, CJ | 1 |
| Kuittinen, T | 1 |
| Jantunen, E | 1 |
| Vanninen, E | 1 |
| Mussalo, H | 1 |
| Vuolteenaho, O | 1 |
| Ala-Kopsala, M | 1 |
| Nousiainen, T | 1 |
| Hartikainen, J | 1 |
| Supko, JG | 1 |
| Phillips, LR | 1 |
| Malspeis, L | 1 |
| Stegman, LD | 1 |
| Taylor, JM | 1 |
| Robertson, PL | 1 |
| Greenberg, HS | 1 |
| Gomez-Manzano, C | 1 |
| Lemoine, MG | 1 |
| Hu, M | 1 |
| He, J | 1 |
| Mitlianga, P | 1 |
| Liu, TJ | 1 |
| Yung, AW | 1 |
| Fueyo, J | 1 |
| Groves, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980] | 32 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for carmustine and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
Assessment of multiexponential diffusion features as MRI cancer therapy response metrics.
Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Diffusion Magn | 2010 |
Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; | 2006 |
Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma.
Topics: Animals; Antineoplastic Agents; Carmustine; Chromatography, High Pressure Liquid; Dogs; Humans; Male | 1996 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |